University of Wisconsin Hospital
Welcome,         Profile    Billing    Logout  
 13 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Harari, Paul M
NRG-HN001, NCT02135042: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Active, not recruiting
2/3
685
Canada, US, RoW
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Clinical Observation, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Actino-Hermal, Adrucil, Arumel, Cytosafe, Efudex, Efurix, Fiverocil, Fluoro Uracil, Fluoroplex, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Flurox, Ribofluor, Ro 2-9757, Ro-2-9757, Timazin, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment
NRG Oncology, National Cancer Institute (NCI)
Epstein-Barr Virus Infection, Stage II Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma, Stage IVA Nasopharyngeal Carcinoma, Stage IVB Nasopharyngeal Carcinoma
02/26
02/31
RTOG 1216, NCT01810913: Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Recruiting
2/3
613
Canada, US, RoW
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cetuximab, C 225, C-225, C225, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI), NRG Oncology
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
01/27
01/27
NRG-HN009, NCT05050162: Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Recruiting
2/3
464
Europe, Canada, US, RoW
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
NRG Oncology, National Cancer Institute (NCI)
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary
02/31
02/36
NCT04936841: Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

Terminated
2
5
US
NKTR-214, bempegaldesleukin, anti-PD-1 therapy, Pembrolizumab, Palliative Radiation
University of Wisconsin, Madison, Nektar Therapeutics
Head and Neck Cancer
10/22
10/22
Drolet, Beth A
EPIK-P2, NCT04589650 / 2020-000561-16: Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

Recruiting
2
205
Europe, Canada, US, RoW
Alpelisib, Placebo
Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
03/24
04/31
NCT04772911: Multicenter Phenotype-Genotype Analysis of Vascular Stains to Optimize Treatment Utilizing Optical Coherence Tomography

Active, not recruiting
N/A
73
US
Optical Coherence Tomography (OCT)
University of Wisconsin, Madison
Vascular Stains
04/25
04/27
Hammill, Adrienne
EPIK-L1, NCT05948943: Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Recruiting
2/3
230
Europe, US, RoW
Alpelisib, BYL719, Placebo
Novartis Pharmaceuticals
Lymphatic Malformations
10/27
05/30
EPIK-P2, NCT04589650 / 2020-000561-16: Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

Recruiting
2
205
Europe, Canada, US, RoW
Alpelisib, Placebo
Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
03/24
04/31
NCT04717427: Longitudinal Studies to Identify Biomarkers for Sturge-Weber Syndrome

Recruiting
N/A
250
US
University of Illinois at Chicago, University of California, San Francisco, Wayne State University, Duke University, Hugo W. Moser Research Institute at Kennedy Krieger, Inc., Children's Hospital Medical Center, Cincinnati, Boston Children's Hospital, Nationwide Children's Hospital, Sturge-Weber Foundation
Sturge-Weber Syndrome
06/25
06/25
BVMN6203, NCT01158807: Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia

Recruiting
N/A
1800
Europe, Canada, US
Unity Health Toronto, National Institute of Neurological Disorders and Stroke (NINDS)
Hereditary Hemorrhagic Telangiectasia
12/24
06/25
NCT03001180: Identification of Biomarkers for Patients with Vascular Anomalies

Recruiting
N/A
1000
US
Children's Hospital Medical Center, Cincinnati, Lymphangiomatosis and Gorham's Disease Alliance (LGDA), Klippel Trenaunay (KT) Support Group, CLOVES Syndrome Community Support Group
Vascular Anomaly, Generalized Lymphatic Anomaly, Kaposiform Hemangioendothelioma, Kaposiform Lymphangiomatosis, Gorham-Stout Disease, Klippel Trenaunay Syndrome, Congenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal Nevi
12/50
12/50
Safdar, Nasia
NCT03617445: Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

Terminated
2
3
US
FMT oral capsule, MTP-101-C, Oral Vancomycin, vancomycin, FMT oral placebo, Placebo MTP-101-C, Oral Vancomycin placebo, placebo
University of Wisconsin, Madison, National Institute of Allergy and Infectious Diseases (NIAID)
Clostridium Difficile Infection Recurrence
06/23
06/23
NCT03462459: Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

Completed
2
54
US
Vancomycin, Vancomycin Hydrochloride, Vancocin, Placebo
University of Wisconsin, Madison, Medical College of Wisconsin, Agency for Healthcare Research and Quality (AHRQ), Henry Ford Hospital, Mayo Clinic
Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection, CDI, C.Difficile Diarrhea, C. Diff Colitis, C.Difficile Colitis
07/23
07/23
NCT05820893: Resistant Potato Starch to Alleviate GWI

Not yet recruiting
2
52
US
Resistant Potato Starch, MSPrebiotic
VA Office of Research and Development
Gulf War Illness
08/25
08/26
GLORI, NCT04036058: Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA

Active, not recruiting
N/A
10
US
Universal gloving, Expanded barrier precautions
VA Office of Research and Development, University of Wisconsin, Madison
Clostridium Difficile
12/23
09/24
FIRST, NCT03848689: FQ Restriction for the Prevention of CDI

Completed
N/A
5871
US
fluoroquinolone preprescription authorization, FQ PPA, Control, No FQ PPA
University of Wisconsin, Madison, Agency for Healthcare Research and Quality (AHRQ)
Clostridium Difficile, Clostridium Difficile Infection, C Difficile Colitis
05/24
05/24
NCT03325855: Fecal Microbiota Transplant National Registry

Recruiting
N/A
4000
Canada, US
None - Observational, Observational
American Gastroenterological Association, OpenBiome, University of California, San Diego, Commure, University of Pennsylvania, University of Minnesota, Loyola University Chicago
Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
08/27
08/27
Ark, Cassondra Vander
NCT02438306: CardiAMP™ Cell Therapy for Heart Failure Trial

Active, not recruiting
3
125
Canada, US
Autologous cell therapy, Sham
BioCardia, Inc.
Heart Failure, Systolic
12/24
12/26
CardiAMP CMI, NCT03455725: CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial

Recruiting
N/A
343
US
CardiAMP Cell Therapy System, Sham Treatment
BioCardia, Inc.
Refractory Angina, Chronic Myocardial Ischemia
07/25
12/26
Baber, Aurangzeb
NCT05983250: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

Recruiting
3
152
Canada, US
TNX-103, Placebo
Tenax Therapeutics, Inc., Medpace, Inc., Northwestern University
Pulmonary Hypertension
03/27
07/27
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Active, not recruiting
2
456
Europe, Canada, Japan, US, RoW
LY3540378, Placebo
Eli Lilly and Company
Heart Failure, Heart Failure With Preserved Ejection Fraction
01/25
01/25
Ott, Debra
EPIK-P2, NCT04589650 / 2020-000561-16: Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

Recruiting
2
205
Europe, Canada, US, RoW
Alpelisib, Placebo
Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
03/24
04/31
Churpek, Matthew
NCT05988658: Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients

Recruiting
N/A
800
US
ESTOP - AKI 2.0
University of Chicago, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Wisconsin, Madison
Acute Kidney Injury, Biomarkers
03/27
03/28
Ogus, Madeline
NCT05988658: Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients

Recruiting
N/A
800
US
ESTOP - AKI 2.0
University of Chicago, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Wisconsin, Madison
Acute Kidney Injury, Biomarkers
03/27
03/28
Anjorin, Ola
NCT05988658: Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients

Recruiting
N/A
800
US
ESTOP - AKI 2.0
University of Chicago, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Wisconsin, Madison
Acute Kidney Injury, Biomarkers
03/27
03/28
Hart, Lily
EPIK-P2, NCT04589650 / 2020-000561-16: Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

Recruiting
2
205
Europe, Canada, US, RoW
Alpelisib, Placebo
Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
03/24
04/31

Download Options